Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults

NCT02067767 is registered in ClinicalTrials.gov with Nantes University Hospital as lead sponsor.

NCT NCT02067767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02067767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults
Lead sponsor
Nantes University Hospital
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2014
Completion date
December 31, 2015
Enrollment
53 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1 infection